OCREVUS is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Ocrelizumab.
Product ID | 50242-150_07f1b276-8bb3-4243-8cc7-4c9262e5fdfe |
NDC | 50242-150 |
Product Type | Human Prescription Drug |
Proprietary Name | OCREVUS |
Generic Name | Ocrelizumab |
Dosage Form | Injection |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2017-03-28 |
Marketing Category | BLA / BLA |
Application Number | BLA761053 |
Labeler Name | Genentech, Inc. |
Substance Name | OCRELIZUMAB |
Active Ingredient Strength | 300 mg/10mL |
Pharm Classes | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC],Antibodies, Monoclonal [CS],Antibodies, Monoclonal, Humanized [CS] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2017-03-28 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | BLA |
Application Number | BLA761053 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2017-03-28 |
Ingredient | Strength |
---|---|
OCRELIZUMAB | 300 mg/10mL |
SPL SET ID: | 9da42362-3bb5-4b83-b4bb-b59fd4e55f0d |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
OCREVUS 87125369 not registered Live/Pending |
Genentech, Inc. 2016-08-03 |
OCREVUS 86205182 5276659 Live/Registered |
GENENTECH, INC. 2014-02-26 |